NuVue Therapeutics Inc.
This article was originally published in Start Up
A game-changing, silver-bullet approach for diagnosing and treating soft-tissue cancers could replace traditional biopsy techniques and IV chemotherapy. Or so hopes NuVue Therapeutics Inc., which is developing a suite of products that could allow more precise tissue removal through an ultrasound-guided needle with color monitoring for easy visibility, plus reduce the current high rates of toxicity and morbidity associated with chemotherapy. The company says its technology enables very low-volume/highly concentrated dosing, just 1/200th to 1/500th of the standard dose of systemic chemotherapy.
You may also be interested in...
A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.